CAS: 40320-60-3; 1-Benzhydrylazetidin-3-One

该化合物是一个化学化合物,其特点是有四人组成的环环形结构,有四人环状矿,该化合物具有苯基基组,表明一个联苯组附于碳,该碳也附着于另一个苯基组,有助于其独特的特性.亚丁酮团表示,它含有一个碳基(C=O),位于青丁环的三处,可影响其回活动及有机合成的潜在应用.芳香和液态成分在其结构中的存在可能会产生有趣的药用特性,使其成为医药化学的一个主题.此外,该化合物的稳定性,溶解性和再活性可能因环境条件和功能组的存在而不同.

英文名称1-Benzhydrylazetidin-3-One
中文名称1-二苯甲基氮杂环丁烷-3-酮
IUPAC名称1-benzhydrylazetidin-3-one
其它别名1-二苯甲基-3-氮杂环丁酮; 3-Azetidinone, 1-(Diphenylmethyl)-
CAS编号40320-60-3
MFCD编号:MFCD00964539
EINECS号:692-488-2
分子式:C16H15NO
分子量:237.3
产品CID: 1416406
产品分类有机原料→分子砌块→芳环类化合物→苯类化合物

相似结构搜索
InChIKey: AVUDXLOVIBJFQA-UHFFFAOYSA-N
InChI=1S/C16H15NO/c18-15-11-17(12-15)16(13-7-3-1-4-8-13)14-9-5-2-6-10-14/h1-10,16H,11-12H2…
计算化学: 氢键受体数2.0氢键供体数0.0可旋转键数3.0

MSDS等安全信息

GHS象形图
GHS符号GHS07;
注释: Exclamation mark
危险类别急性毒性类别4(经口)
急性毒性类别4(吸入)
急性毒性类别4(经皮)
特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼刺激类别2
严重眼刺激类别2A
警示词Warning(警告)
危险描述H302 |吞咽有害.
H332 |吸入有害.
H312 |皮肤接触有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险等级IRRITANT
安全声明24/25

欧盟法规

ECHA物质C&L通报

上下游产品

合成工艺路线路线简述

合成目标产物 1-Benzhydrylazetidin-3-One 主要起始原料 1-Benzhydrylazetidin-3-Ol
(文献来源)合成步骤主要原料 1-Benzhydrylazetidin-3-Ol

二苯甲胺盐酸盐置于sodium Hydroxide体系中,用二氯甲烷,Alkaline Aq. Solution,水作为反应溶剂,化学反应 87.0H,反应生成 1-二苯甲基氮杂环丁烷-3-酮
参考文献:一种制备3-氮杂环丁烷乙酸的简便方法
标题:一种制备3-氮杂环丁烷乙酸的简便方法
摘要:描述了从市售环氧氯丙烷制备新型 3-氮杂环丁烷乙酸的简便途径.
DOI:10.1246/cl.1999.605

海关参考信息

2902300000-甲苯
2912110000-甲醛
2912120000-乙醛
2914110000-丙酮
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:WO-2018108954-A1
优先权日:2016-12-12
标题 :Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
发明人：GOSSELIN FRANCIS; LINGHU XIN
权利人:HOFFMANN LA ROCHE; GENENTECH INC
摘要:Methods of making 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol 9, an intermediate useful for the synthesis of estrogen receptor modulating compounds are described.

专利号:NZ-547194-A
优先权日:2003-12-02
标题:Process for converting heterocyclic ketones to amido-substituted heterocycles that are used as intermediates in the synthesis of cannabinoid (CB-1) antagonists

专利号:US-6255315-B1
优先权日:1997-06-18
标题:Alpha 1a adrenergic receptor antagonists
发明人：PATANE MICHAEL A; SELNICK HAROLD G; BOCK MARK G
权利人:MERCK & CO INC
摘要:This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha relductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

专利号:US-9428490-B2
优先权日:2011-07-29
标题 :Nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; KAUFFMAN MICHAEL; SHECHTER SHARON; MCCAULEY DILARA; LANDESMAN YOSEF; SENAPEDIS WILLIAM; SAINT-MARTIN JEAN-RICHARD; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.